Independent evidence guide
A close reading of follow-up research, recovery accounts, safety limits, and the conditions that complicate claims about lasting change after ibogaine.
!Ibogaine remains investigational and high risk. This resource is for understanding evidence, not for making treatment decisions or replacing medical care.
Reading the evidence
Ibogaine is a psychoactive indole alkaloid derived from Tabernanthe iboga. Its long-term outcomes matter because an acute detox or striking subjective experience is not the same thing as sustained remission from addiction.
Useful follow-up asks what happened at 30 days, three months, a six-month follow-up, and twelve-month outcomes. It separates abstinence rates from reduced use, self-report from toxicology-verified outcomes, and medically supervised dosing from unregulated retreat use.
For opioid use disorder, that distinction is especially important. Withdrawal symptoms can change quickly, while housing, employment, psychiatric care, medication access, and exposure to fentanyl or heroin can shape patient outcomes for months.
Ibogaine follow-up literature is dominated by observational study designs, retrospective reports, and case studies. These longitudinal studies can identify patterns worth testing, but they cannot reliably isolate drug effect from selection, expectation, concurrent psychotherapy, or regression to the mean.
Observed cohorts
A landmark prospective observational study associated with the Multidisciplinary Association for Psychedelic Studies’ Mexico follow-up work is often discussed beside a New Zealand cohort.
In the New Zealand follow-up, approximately 50 percent of participants assessed were reported to have sustained abstinence from opioids at the 12-month follow-up mark. That figure is promising, but it is not a general success rate for ibogaine or opioid use disorder.
Research tracking patients treated in Mexico reported lower Addiction Severity Index composite scores at one, three, six, and twelve months compared with baseline.
The twelve-month observational follow-up paper illustrates both the appeal of repeated measures and the central problem of attrition in longitudinal studies.
Observational registries often show relapse concentrated between three and six months when active integration therapy or social support structures are absent.
Abstinence rates should therefore be read beside who completed follow-up, who entered aftercare, who resumed buprenorphine or methadone, and whether participants returned to the environments associated with prior addiction.
Longer exposure is a pharmacokinetic question, not proof of durable recovery.
Mechanisms and claims
Ibogaine is rapidly metabolized in the liver by CYP2D6 into noribogaine. Noribogaine is commonly described as a potent serotonin reuptake inhibitor and mu-opioid receptor partial agonist, making it central to accounts of lingering changes in cravings after detox.
Noribogaine has a prolonged terminal elimination half-life and may be sequestered in adipose tissue. This proposed slow-release depot effect is often used to explain craving reduction for weeks or months, although individual exposure and patient outcomes vary.
At the receptor level, ibogaine and noribogaine have been discussed in relation to the serotonin transporter, the kappa opioid receptor, dopamine pathways, and the NMDA receptor. These mechanisms are biologically interesting; they do not establish long-term remission in clinical trials.
Preclinical research also links ibogaine with increased GDNF expression—glial cell line-derived neurotrophic factor—in the ventral tegmental area. The hypothesis is that neuroplasticity in dopaminergic circuits may support a reset in learned drug response, but animal and mechanistic findings cannot substitute for controlled longitudinal studies.
Descriptions of an acute oneiric state and powerful subjective effects appear frequently in case studies. Some people interpret autobiographical material as relevant to trauma or addiction; others do not. A clear account needs to distinguish psychedelic therapy narratives from measured, sustained abstinence.
Safety is part of every outcome
Ibogaine has an inherent risk of cardiotoxicity. Dose-dependent hERG potassium-channel blockade can produce QTc prolongation, and severe QTc prolongation can contribute to fatal arrhythmias. This is not a peripheral concern that can be balanced away by a hopeful follow-up story.
Clinical protocols require medical screening, baseline 12-lead electrocardiogram assessment, review of all medications, liver function tests, electrolyte balance, and attention to hypokalemia. Continuous telemetry and repeat electrocardiogram monitoring are commonly cited safeguards while ibogaine and noribogaine are at high plasma levels.
Case-review literature includes deaths following iboga exposure; one fatal withdrawal-treatment case analysis underscores why crude preparations, unknown alkaloid exposure, co-occurring illness, and drug interactions cannot be treated casually.
“For whom, under what medical conditions, with what aftercare, and with what probability of durable benefit relative to fatal cardiac risk?”
QTc prolongation risk is amplified by preexisting cardiovascular disease, hypokalemia, dehydration, and concurrent QTc-prolonging pharmaceuticals. Cardiotoxicity and fatal arrhythmias make unscreened use particularly hazardous, even where ibogaine is framed as a detox alternative.
There is also a longer-term overdose issue. Ibogaine can produce tolerance reduction after acute withdrawal. If a person returns to fentanyl, heroin, or other opioids at pre-treatment amounts, the risk of fatal overdose or fatal respiratory depression may be elevated.
What follows the session
Acute withdrawal can resolve after ibogaine without resolving substance use disorder. Comparing short-term detox to long-term outcomes requires tracking relapse, medication use, overdose, treatment engagement, quality of life, and functioning—not only days without opioids.
Long-term outcomes tend to look stronger when people transition promptly into sober living, stable housing, or another structured environment rather than returning to the same social conditions that supported addiction.
Psychotherapeutic integration may include psychotherapy, cognitive behavioral therapy, peer-support groups, somatic approaches, harm reduction education, and a relapse plan. These supports address triggers and distress that an acute psychedelic therapy experience cannot remove.
Buprenorphine and methadone are evidence-based treatments for opioid use disorder. A follow-up case should document whether medication was continued, discontinued, restarted after relapse, or avoided, rather than presenting all medication changes as evidence of remission.
People comparing support pathways can use the resource-navigation approach to organize questions about follow-up, screening, and aftercare without confusing information with a treatment recommendation.
For people looking broadly at location and oversight questions, considerations around where ibogaine treatment occurs belong alongside concerns about medical screening, clinical protocols, and continuity of care.
Secondary outcomes
Longitudinal studies sometimes report lower depression and anxiety scores after ibogaine. Some registries describe reductions on the Beck Depression Inventory and Hamilton Anxiety Rating Scale through twelve-month outcomes, alongside improved subjective well-being and quality of life.
Those measures remain secondary outcomes, not proof that ibogaine treats depression, anxiety, or treatment-resistant conditions. People with post-traumatic stress disorder, PTSD, bipolar-spectrum vulnerability, psychosis risk, or complex medication regimens need especially careful clinical assessment.
A recent Stanford account of veteran research discusses follow-up findings involving ibogaine combined with 5-MeO-DMT, including sustained decreases in PTSD symptoms and cognitive impairment at a six-month follow-up. Such work is notable, yet it remains distinct from confirming broad effectiveness.
Qualitative reports may describe an oneiric state as foundational to trauma processing. A rigorous observational study should still ask whether depression, anxiety, PTSD symptoms, employment, executive functioning, and quality of life improved independently of changing substance use.
For a neutral explanation of why evidence hierarchies matter, the National Library of Medicine overview of clinical research design helps clarify why uncontrolled patient outcomes cannot settle causal questions.
Ibogaine remains a Schedule I controlled substance in the United States. It is used under different legal and medical arrangements in places including New Zealand and Mexico, but legality does not itself establish safety, clinical protocols, or efficacy.
The peer-reviewed review available through PubMed Central describes the scientific and safety context around ibogaine, including the importance of cardiovascular risk.
Observational cohort registries can capture follow-up patterns across real settings. They can also conceal missing data, inconsistent dosing, polysubstance use, unmeasured aftercare, and different definitions of abstinence rates.
As of this evidence landscape, clinical trials have not established ibogaine as a comparative, long-term treatment for addiction. A recent journal publication on ibogaine evidence is relevant to the continuing need for controlled research and transparent adverse-event reporting.
About this resource
Sustainogaine Outcomes is a newly launched independent information company for people trying to understand long-term ibogaine outcomes: follow-up cases with more clarity and less hype. Our principles for assessing difficult evidence explain why safety, uncertainty, and missing follow-up data stay visible here.
Recovery stories can be meaningful without functioning as proof. Collections such as published ibogaine success narratives can reveal what people value in their own words, but they should not be interpreted as representative abstinence rates or a guarantee of remission.
Similarly, clinic-facing ibogaine case studies may offer descriptive context while leaving open questions about selection, adverse events, follow-up completeness, and relapse outside the reported window.
The core task is to hold two facts at once: some follow-up cases describe substantial changes in cravings, withdrawal symptoms, addiction severity, depression, and quality of life; and the available longitudinal studies remain too limited to convert those observations into an established addiction cure.
For background on the drug itself, the general ibogaine reference overview provides a starting definition, while medical decisions require qualified, individualized care.
Interpretive FAQ
Longitudinal studies suggest that some participants report reduced opioid use, fewer withdrawal symptoms, craving reduction, and better patient outcomes months after ibogaine. A twelve-month observational study in New Zealand is often cited because approximately 50 percent of assessed participants reported sustained abstinence from opioids at follow-up.
That is not a definitive long-term success rate. Small samples, incomplete follow-up, no randomization, and variable aftercare mean abstinence rates cannot be generalized to everyone with opioid use disorder.
Noribogaine is the primary active metabolite of ibogaine and has a longer exposure profile. Its effects on the serotonin transporter, mu-opioid signaling, dopamine-related systems, and the kappa opioid receptor are proposed contributors to protracted craving reduction.
The depot-effect explanation is plausible but incomplete. Noribogaine exposure does not replace aftercare, and it does not guarantee remission or prevent relapse in the presence of stress, psychiatric symptoms, or ready access to fentanyl, heroin, or other drugs.
Aftercare makes the difference between a narrow detox event and an ongoing recovery plan. Psychotherapeutic integration, psychotherapy, cognitive behavioral therapy, harm reduction, peer support, and stable housing can help address the conditions that drive relapse.
Follow-up patterns commonly suggest that relapse risk rises around three to six months when social support and integration therapy are absent. Returning immediately to a previous environment can overwhelm any temporary reduction in cravings.
The primary acute medical concern is cardiotoxicity: QTc prolongation can lead to fatal arrhythmias, particularly with hypokalemia, cardiac disease, or interacting medications. Medical screening, liver function tests, electrolyte balance, and repeated electrocardiogram monitoring are essential safety concepts.
Longer-term risk also includes fatal overdose after tolerance reduction if relapse occurs at a pre-treatment dose. Psychiatric risks include worsening anxiety, depression, PTSD symptoms, impaired judgment, or destabilization in vulnerable people. The discussion of long-term recovery outcomes should be weighed against these hazards rather than read as a safety assurance.
No. Documentary accounts can communicate subjective effects, the oneiric state, or a personal path away from addiction, but they cannot establish causal efficacy, comparative benefit, abstinence rates, or safety incidence. An ibogaine documentary listing is cultural context rather than a clinical evidence source.
Long-term outcomes deserve measurement beyond detox: sustained abstinence, relapse, overdose risk, depression, anxiety, PTSD, quality of life, medication changes, safety events, and the aftercare surrounding every follow-up case.
Explore aftercare and confounders